var data={"title":"Tiopronin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tiopronin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7060?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tiopronin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tiopronin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228218\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Thiola</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228232\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Urinary Tract Product</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228220\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage should be adjusted to reduce urinary cystine level to below the solubility limit (generally &lt;250 mg/L).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of nephrolithiasis (cystine):</b> Oral: Initial: 800 mg/day in 3 divided doses; average dose: 1000 mg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12595418\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage should be adjusted to reduce urinary cystine level to below the solubility limit (generally &lt;250 mg/L).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of nephrolithiasis (cystine):</b> Oral: Children &ge;9 years: Initial: 15 mg/kg/day in 3 divided doses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228221\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228213\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thiola: 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228205\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12595443\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer 1 hour before or 2 hours after meals. A conservative approach of at least 3 L of fluid intake (ten 10-ounce glassfuls) to achieve a minimum urine output of 2 L/day should be tried prior to initiating therapy; patients continuing to form cystine stones while using this approach may be started on tiopronin. At least 3 L of daily fluid intake should continue while taking tiopronin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228214\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prevention of kidney stone (cystine) formation in patients with severe homozygous cystinuria who have urinary cystine &gt;500 mg/day who are resistant to treatment with high fluid intake, alkali and diet modification, or who have had adverse reactions to penicillamine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      Note: Based on the American Urologic Association (AUA) guidelines for the medical management of kidney stones (http://www.auanet.org/common/pdf/education/clinical-guidance/Medical-Management-of-Kidney-Stones.pdf), tiopronin is recommended as the agent of choice for the prevention of recurrent cystine stones in patients that are unresponsive to increased fluid intake, restriction of sodium and protein intake, and urinary alkalinization or who have large recurrent stone burdens (AUA [Pearle, 2014]; Pak 1986).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12595320\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anosmia, chills, fatigue, myasthenia gravis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Fragile skin, pemphigus, pruritus, skin rash, urticaria, warts, wrinkling of skin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, ageusia, anorexia, bloating, diarrhea, flatulence, nausea, oral mucosa ulcer, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Goodpasture's syndrome, hematuria, nephrotic syndrome, proteinuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, bruise, eosinophilia, hemorrhage, leukopenia, lymphadenopathy, positive ANA titer, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, connective tissue disease (elastosis perforans serpiginosa), lupus-like syndrome, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchiolitis, dyspnea, hemoptysis, laryngeal edema, pharyngitis, pulmonary infiltrates, respiratory distress</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12593125\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Prior history of developing agranulocytosis, aplastic anemia, or thrombocytopenia on this medication; pregnancy, except in severe cystinuria where the benefit of inhibited stone formation outweighs the risk of treatment; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12593745\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Goodpasture&rsquo;s syndrome: Penicillamine has rarely been associated with fatalities due to Goodpasture&rsquo;s syndrome; therefore, the potential of Goodpasture&rsquo;s syndrome in tiopronin treated patients is possible; discontinue therapy if signs or symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Signs of toxicity include leukopenia without eosinophilia and thrombocytopenia. Contraindicated in patients with a history of blood dyscrasias (eg, aplastic anemia, agranulocytosis, thrombocytopenia). Advise patients to report early signs and symptoms including fever, sore throat, mouth ulcers, infections, easy bruising, petechial or purpuric hemorrhage. Therapy should be discontinued if platelet count falls to &lt;100,000/mm<sup>3</sup> or WBC &lt;3500/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Penicillamine has rarely been associated with fatalities due to myasthenia gravis; therefore, the potential of myasthenia gravis in tiopronin-treated patients is possible; discontinue therapy if signs or symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pemphigus: Discontinue treatment if pemphigus-type reactions occur; additional therapy may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proteinuria: Proteinuria may develop; monitor for membranous glomerulopathy which can lead to nephrotic syndrome.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300144\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6223334\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10287&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228210\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12593115\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects, including skeletal defects and cleft palates, have been observed following penicillamine exposure in animal reproduction studies. Birth defects, including congenital cutix laxa and associated defects, have been reported in infants following penicillamine exposure during pregnancy. Similar effects may be expected with tiopronin; however, animal studies have not shown these same findings. Use is contraindicated during pregnancy; use only if the possible benefits to the mother outweigh the potential risks to the fetus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17917864\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Tiopronin may be excreted in breast milk; therefore, use while breast-feeding is contraindicated by the manufacturer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12595442\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Should be taken 1 hour before or 2 hours after meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12595452\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, platelet count, hemoglobin, albumin, liver function tests, 24-hour urinary protein, and routine urinalysis should be performed at 3- to 6-month intervals; urinary cystine 1 month after treatment begins then every 3 months; annual X-ray for renal stones</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12595410\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">As an active reducing agent, tiopronin undergoes thiol-disulfide exchange with cystine to form tiopronin-cystine disulfide, which is more water soluble than cystine. As a result, the amount of sparingly soluble cystine in the urine is decreased and the formation of cystine calculi is reduced.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5574863\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Thiola Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $3,385.10</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228216\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acadione (FR);</li>\n      <li>Capen (AR);</li>\n      <li>Captimer (DE);</li>\n      <li>Chiosol (BD);</li>\n      <li>Epatiol (IT);</li>\n      <li>Kai Na (CN);</li>\n      <li>Kai Xi Lai (CN);</li>\n      <li>Mucolysin[chart.] (CH, IT);</li>\n      <li>Mucosyt (IT);</li>\n      <li>Orin (BD);</li>\n      <li>Stargen (TW);</li>\n      <li>Sutilan (ES);</li>\n      <li>Thiola (BE, JP);</li>\n      <li>Vincol (ES)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Pak CY, Fuller C, Sakhaee K, Zerwekh JE, Adams BV. Management of cystine nephrolithiasis with alpha-mercatopropionylglycine. <i>J Urol</i>. 1986;136(5):1003-1008.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tiopronin-drug-information/abstract-text/3534301/pubmed\" target=\"_blank\" id=\"3534301\">3534301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pearle MS, Goldfarb DS, Assimos DG, et al. Medical Management of Kidney Stones: AUA Guideline. 2014. http://www.auanet.org/common/pdf/education/clinical-guidance/Medical-Management-of-Kidney-Stones.pdf. Accessed September 4, 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10287 Version 70.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F228218\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F228232\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F228220\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F12595418\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F228221\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F228213\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F228205\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F12595443\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F228214\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F12595320\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F12593125\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F12593745\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300144\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6223334\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F228210\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F12593115\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F17917864\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F12595442\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F12595452\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F12595410\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5574863\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F228216\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10287|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tiopronin-patient-drug-information\" class=\"drug drug_patient\">Tiopronin: Patient drug information</a></li></ul></div></div>","javascript":null}